🇺🇸 FDA
Pipeline program

Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)

MCC-21894

Phase 1 mab active

Quick answer

Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL) for Urothelial Carcinoma is a Phase 1 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Urothelial Carcinoma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials